DEV Community: phenix samsung

Chromatography Instrumentation Market Revenue Expected to Reach US$ 14.3 Billion

phenix samsung — Fri, 29 May 2026 11:44:43 +0000

Report Overview

The Global Chromatography Instrumentation Market size is expected to be worth around US$ 14.3 Billion by 2035 from US$ 8.4 Billion in 2025, growing at a CAGR of 5.5% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 41.1% share with a revenue of US$ 3.5 Billion.

The global Chromatography Instrumentation Market is witnessing significant growth due to rising demand for advanced analytical technologies in pharmaceutical, biotechnology, environmental, and food testing industries. Chromatography instruments are widely used for separating, identifying, and analyzing chemical compounds with high precision, making them essential in drug development, clinical diagnostics, and quality control applications.

The market generated revenue of US$ 8.4 Billion in 2025 and is projected to reach US$ 14.3 Billion by 2035, expanding at a CAGR of 5.5% during the forecast period. Increasing pharmaceutical research activities, growing biologics production, and stringent regulatory requirements for product safety are major factors driving market expansion. Liquid chromatography emerged as the leading chromatography system segment, accounting for 46.8% of the market share owing to its broad application in pharmaceutical analysis and laboratory testing.

North America dominated the market with a 41.1% share, supported by strong healthcare infrastructure, advanced research facilities, and increasing investment in analytical laboratory technologies. Continuous technological advancements in chromatography systems are expected to further support long-term market growth globally.

Click here for more information: https://market.us/report/chromatography-instrumentation-market/

Key Takeaways

In 2025, the market generated revenue of US$ 8.4 Billion and is projected to reach US$ 14.3 Billion by 2035, expanding at a CAGR of 5.5% during the forecast period.
By chromatography systems, the market is segmented into liquid chromatography, thin-layer chromatography, gas chromatography, and supercritical fluid chromatography. Among these, liquid chromatography dominated the segment with a 46.8% market share.
Based on consumables, the market is categorized into columns, solvents, syringes, and others. The columns segment accounted for the largest share of 52.3%.
In terms of accessories, the market is divided into column accessories, pumps, auto-sampler accessories, and others. Column accessories emerged as the leading segment, capturing 38.6% of the total revenue share.
By application, the market is segmented into pharmaceutical firms, agriculture, clinical research organizations, and environmental testing. Pharmaceutical firms held the dominant position with a revenue share of 44.5%.
North America emerged as the leading regional market, accounting for 41.1% of the overall market share in 2025.

Key Market Segments

Liquid Chromatography
Thin-Layer Chromatography
Gas Chromatography
Supercritical Fluid Chromatography
By Consumables
Columns
Solvents
Syringes
Others
By Accessories
Column Accessories
Pumps
Auto-Sampler Accessories
Others
By Application
Pharmaceutical firms
Agriculture
Clinical research organizations
Environmental Testing

Market Key Players

Agilent Technologies
Shimadzu Corporation
Thermo Fisher Scientific
Waters Corporation
PerkinElmer
Metrohm
Hitachi High‑Tech
JASCO
Bio‑Rad Laboratories
Knauer Wissenschaftliche Geräte

**
Get a Sample Copy of the Report to Know More: https://market.us/report/chromatography-instrumentation-market/free-sample/**

Market Dynamics

Driver

The growing demand for pharmaceutical quality testing and biologics development is a major driver for the chromatography instrumentation market. Chromatography systems are extensively used in drug discovery, impurity profiling, vaccine development, and bioanalytical testing. Regulatory agencies such as the U.S. Food and Drug Administration require validated analytical methods for pharmaceutical products, increasing the adoption of high-performance liquid chromatography (HPLC) and gas chromatography (GC) systems. The FDA’s M10 Bioanalytical Method Validation guidance emphasizes chromatographic assays for nonclinical and clinical studies, highlighting their importance in regulatory submissions.

The rapid rise in chronic diseases is also increasing pharmaceutical R&D spending worldwide. According to the World Health Organization, cancer caused nearly 10 million deaths globally in 2022, creating strong demand for advanced analytical testing during drug development. Chromatography instruments help ensure drug purity and safety at trace levels. In addition, government-funded laboratory programs and clinical testing initiatives continue to expand analytical laboratory capacity. Increasing biologics production, precision medicine research, and biosimilar approvals are therefore accelerating the need for reliable chromatography instrumentation across pharmaceutical and biotechnology industries.

Trend

One major trend in the chromatography instrumentation market is the integration of chromatography with mass spectrometry and automation technologies. Laboratories are increasingly adopting LC-MS and GC-MS systems because they provide highly accurate detection of complex compounds at extremely low concentrations. Environmental agencies such as the U.S. Environmental Protection Agency use gas chromatography-mass spectrometry methods like EPA Method 8260D and 8270E for detecting volatile and semivolatile organic compounds in water, soil, and environmental samples.

Automation is another important market trend. Modern chromatography systems now include auto-samplers, AI-supported software, cloud-based monitoring, and digital data management solutions that improve laboratory efficiency and reduce human error. Clinical laboratories are increasingly processing large sample volumes, driving demand for automated work flows. According to the CDC test directory, hundreds of laboratory tests are performed across infectious disease and clinical research programs, supporting the need for advanced analytical infrastructure.

Miniaturized chromatography systems and ultra-high-performance liquid chromatography platforms are also gaining popularity because they offer faster analysis times, lower solvent consumption, and higher sensitivity. These innovations are improving productivity while reducing operational costs for pharmaceutical, food safety, and environmental testing laboratories worldwide.

Restraint

The high cost of chromatography instrumentation and maintenance remains a significant restraint for market growth. Advanced systems such as LC-MS, GC-MS, and UHPLC instruments require substantial initial investment, often ranging from tens of thousands to several hundred thousand dollars depending on system configuration. In addition to equipment costs, laboratories must spend heavily on consumables, columns, calibration standards, software upgrades, and maintenance contracts.

Operational complexity is another challenge. Chromatography instruments require highly trained professionals for method development, validation, troubleshooting, and interpretation of analytical data. Many small laboratories and healthcare facilities in developing economies face shortages of skilled analytical chemists and laboratory technicians. Improper handling or inadequate validation can affect test accuracy and regulatory compliance. FDA bioanalytical validation guidance places strict requirements on chromatographic assay performance, reproducibility, and calibration standards, increasing operational burden for laboratories.

Environmental testing regulations also demand precise sample preservation and handling procedures. EPA methods for GC/MS testing require strict temperature-controlled sample transport and storage conditions to maintain analytical reliability. These stringent compliance requirements increase operational costs and slow adoption among smaller laboratories. Consequently, budget limitations and technical complexity continue to restrict wider implementation of advanced chromatography systems in cost-sensitive healthcare and research settings.

Opportunity

Expanding environmental monitoring programs and food safety regulations present significant opportunities for the chromatography instrumentation market. Governments worldwide are strengthening regulations for detecting pollutants, pesticides, industrial chemicals, and contaminants in water, soil, and food products. The [U.S. Environmental Protection Agency (EPA)]continues to promote analytical methods such as GC/MS for identifying volatile organic compounds and hazardous substances in environmental samples.

Increasing concerns about water contamination and industrial emissions are driving investments in environmental testing laboratories. Chromatography systems are essential for identifying contaminants at parts-per-billion concentrations, particularly in drinking water monitoring and hazardous waste analysis. Rising food exports and stricter international quality standards are also increasing the use of chromatography in food authenticity testing and pesticide residue analysis.

Another strong opportunity lies in personalized medicine and biomarker research. The growth of genomics, proteomics, and metabolomics research is increasing demand for highly sensitive analytical platforms capable of separating and identifying complex biological compounds. Government-supported healthcare research programs and rising pharmaceutical innovation are expected to further increase analytical testing requirements. Emerging economies in Asia-Pacific and Latin America are also expanding laboratory infrastructure and pharmaceutical manufacturing capacity, creating favorable growth opportunities for chromatography instrument manufacturers over the next decade.

Conclusion

The global Chromatography Instrumentation Market is poised for steady growth over the coming decade, driven by increasing demand for advanced analytical technologies across pharmaceutical, biotechnology, environmental, and food testing industries. The market is expected to expand from US$ 8.4 Billion in 2025 to approximately US$ 14.3 Billion by 2035, registering a CAGR of 5.5% during the forecast period. Rising investments in drug discovery, biologics research, and laboratory automation are significantly contributing to market expansion worldwide.

Liquid chromatography continues to dominate the market due to its broad application in pharmaceutical analysis and clinical research. Additionally, growing regulatory emphasis on product quality, safety testing, and environmental monitoring is increasing the adoption of chromatography systems globally. North America maintained its leadership position in 2025, accounting for 41.1% of the market share with revenue reaching US$ 3.5 Billion, supported by strong healthcare infrastructure and advanced research capabilities. Continuous technological advancements and increasing laboratory modernization initiatives are expected to create substantial opportunities for market players in the coming years.

Bone Densitometer Devices Market to Witness Strong Demand Through 2035

phenix samsung — Fri, 29 May 2026 06:22:31 +0000

Report Overview

The Global Bone Densitometer Devices Market size is expected to be worth around US$ 558.7 Million by 2035 from US$ 366.7 Million in 2025, growing at a CAGR of 4.3% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 36.3% share with a revenue of US$ 133.1 Million.

The global Bone Densitometer Devices Market is witnessing steady growth due to the increasing prevalence of osteoporosis, rising geriatric population, and growing awareness regarding early bone health assessment. Bone densitometer devices are widely used to measure bone mineral density (BMD) and help diagnose bone-related disorders such as osteoporosis and osteopenia. These devices play a critical role in fracture risk assessment and preventive healthcare management.

In 2025, the market generated revenue of US$ 366.7 Million and is projected to reach US$ 558.7 Million by 2035, growing at a CAGR of 4.3% during the forecast period. The market is primarily driven by the growing adoption of dual energy x-ray absorptiometry (DXA) technology, increasing healthcare expenditure, and rising demand for non-invasive diagnostic solutions.

Hospitals remain the leading end-user segment due to the availability of advanced imaging infrastructure and higher patient inflow. North America dominated the market with the largest revenue share, supported by strong healthcare systems, favorable reimbursement policies, and increasing osteoporosis screening programs across the region.A

Click here for more information: https://market.us/report/bone-densitometer-devices-market/

Key Takeaways

In 2025, the Bone Densitometer Devices Market generated revenue of US$ 366.7 Million and is projected to reach US$ 558.7 Million by 2035, expanding at a CAGR of 4.3% during the forecast period.
Based on product type, the market is categorized into axial bone densitometer and peripheral bone densitometer. Among these, the axial bone densitometer segment dominated the market, accounting for a 61.4% share.
By technology, the market is segmented into dual energy x-ray absorptiometry (DXA), peripheral absorptiometry (pDXA), peripheral dual energy x-ray, quantitative ultrasound (QUS), and others. The dual energy x-ray absorptiometry (DXA) segment held the leading position with a 54.7% market share.
In terms of end users, the market is divided into hospitals, diagnostic centers, and orthopedic clinics. Hospitals emerged as the largest segment, capturing 52.8% of the total market revenue.
North America maintained its leading position in the global market, securing a market share of 36.3% in 2025.

Key Market Segments

By Product Type

Axial Bone Densitometer
Peripheral Bone Densitometer
By Technology
Dual Energy X-Ray Absorptiometry (DXA)
Absorptiometry (pDXA)
Peripheral Dual Energy X-Ray
Quantitative Ultrasound (QUS)
Others
By End-User
Hospitals
Diagnostic Centers
Orthopedic Clinics
Market Key Players
Hologic
GE HealthCare
Medtronic
Siemens Healthineers
Furuno Electric
OsteoSys
DMS Group
Lunar (GE)
Osteometer MediTech
D & R Ferreol

Get a Sample Copy of the Report to Know More: https://market.us/report/bone-densitometer-devices-market/free-sample/

Market Dynamics

Driver

The rising global burden of osteoporosis and age-related bone disorders is a major driver for the Bone Densitometer Devices Market. Governments and healthcare organizations are increasingly promoting early diagnosis of osteoporosis to reduce fracture-related healthcare costs and disability. According to the U.S. National Institutes of Health (NIH), osteoporosis weakens bones and significantly increases fracture risk, particularly in the hip, spine, and wrist. NIH data also notes that fracture risk rises by 1.5 to 2 times with every 1-point decline in T-score measured through bone mineral density testing.

The growing elderly population is accelerating demand for bone density screening devices such as Dual-Energy X-ray Absorptiometry (DXA) systems. The World Health Organization and public health agencies emphasize osteoporosis screening among women above 65 years due to higher susceptibility after menopause. In the United States alone, nearly 10 million people are estimated to have osteoporosis, while millions more suffer from osteopenia.

Healthcare systems are also focusing on preventive care and chronic disease management, increasing the installation of DXA scanners in hospitals and diagnostic centers. Rising awareness campaigns regarding bone health, vitamin D deficiency, and fracture prevention further contribute to higher screening volumes globally.

Trend

One of the most significant trends in the Bone Densitometer Devices Market is the integration of artificial intelligence (AI) and portable diagnostic technologies into bone health assessment. Traditional DXA systems remain the gold standard for osteoporosis diagnosis; however, healthcare providers are increasingly adopting compact and portable bone densitometers for community-based screening and outpatient use. NIH reports that peripheral DXA systems measuring wrist and heel bone density are becoming more accessible for rapid screening purposes.

Another emerging trend is opportunistic osteoporosis screening using existing imaging scans combined with AI algorithms. Recent academic research demonstrated AI systems achieving over 90% sensitivity in identifying bone loss from routine knee radiographs, reducing dependence on dedicated imaging appointments. ([arXiv][4]) This advancement may improve osteoporosis detection rates in underserved populations.

Cloud-based imaging software and digital reporting platforms are also gaining traction, enabling faster interpretation of T-scores and patient monitoring. Additionally, healthcare providers are increasingly emphasizing preventive screening among younger at-risk populations, including patients with hormonal disorders, nutritional deficiencies, or long-term steroid use.

The shift toward minimally invasive, low-radiation diagnostic technologies and integration with electronic medical records is expected to improve workflow efficiency and support broader adoption of advanced bone densitometry systems worldwide.

Restraint

Despite growing awareness of osteoporosis, limited screening accessibility and high equipment costs remain major restraints for the Bone Densitometer Devices Market. Advanced DXA systems require significant capital investment, regular calibration, trained radiology professionals, and dedicated infrastructure. These financial barriers are particularly challenging for small clinics and healthcare facilities in low- and middle-income countries.

According to NIH resources, DXA remains the most reliable method for diagnosing osteoporosis and predicting fracture risk. However, many rural regions still lack access to specialized imaging centers, resulting in delayed diagnosis and underreporting of osteoporosis cases. Studies and public health reports indicate that osteoporosis often remains undetected until fractures occur, increasing long-term treatment costs and patient disability.

Another restraint is inconsistent reimbursement policies for bone density testing across healthcare systems. In some countries, insurance coverage is limited to high-risk elderly populations, restricting routine preventive screening among younger adults. Additionally, limited awareness among men regarding osteoporosis risk reduces overall testing demand. NIH highlights that insufficient clinical evidence has historically limited universal screening recommendations for men.

Concerns regarding radiation exposure, although minimal in DXA scans, also discourage frequent testing among some patients. These factors collectively slow the adoption of bone densitometry devices, particularly in developing healthcare markets with constrained diagnostic budgets.

Opportunity

The Bone Densitometer Devices Market presents strong opportunities through expanding preventive healthcare programs and increasing investments in early osteoporosis diagnosis. Governments and healthcare agencies are encouraging routine bone mineral density screening to reduce the economic burden associated with fractures, hospitalization, and long-term rehabilitation. NIH data shows that osteoporosis-related fractures commonly affect the hip and spine, significantly impacting quality of life among aging populations.

Emerging economies represent a major growth opportunity due to improving healthcare infrastructure and rising awareness regarding bone health. Large populations in Asia-Pacific and Latin America are entering older age groups, increasing demand for affordable diagnostic imaging technologies. Portable and low-cost densitometers can help expand screening access in rural and community healthcare settings.

Technological innovation also creates new commercial opportunities. AI-enabled bone density assessment tools, cloud-connected imaging systems, and radiation-efficient devices can enhance diagnostic accuracy and workflow efficiency. Research studies have shown promising results in estimating bone mineral density from routine X-rays with high correlation to DXA measurements.

Additionally, increasing focus on women’s health programs, postmenopausal care, and preventive wellness packages is likely to support higher testing volumes. Partnerships between hospitals, diagnostic centers, and digital health companies may further accelerate adoption of next-generation bone densitometry solutions globally.

Conclusion

The Bone Densitometer Devices Market is expected to experience stable growth over the coming years, supported by the rising prevalence of osteoporosis, increasing aging population, and growing emphasis on preventive healthcare. Advancements in diagnostic imaging technologies, particularly dual energy x-ray absorptiometry (DXA), are improving the accuracy and efficiency of bone mineral density assessment. Healthcare providers are increasingly adopting bone densitometry devices for early diagnosis and fracture risk evaluation, especially among postmenopausal women and elderly patients. Additionally, expanding healthcare infrastructure, growing awareness regarding bone health, and favorable government screening initiatives are contributing to market expansion. North America continues to lead the market due to strong healthcare spending and widespread access to advanced diagnostic systems. However, emerging economies are also presenting significant growth opportunities due to improving healthcare access and rising demand for early osteoporosis detection. Continuous technological innovation and increasing investments in diagnostic imaging are expected to further strengthen the global Bone Densitometer Devices Market during the forecast period.

Biologics Contract Manufacturing Market Accelerates with Rising Outsourcing Demand

phenix samsung — Thu, 28 May 2026 09:55:55 +0000

Report Overview

The Global Biologics Contract Manufacturing Market size is expected to be worth around US$ 94.4 Billion by 2035 from US$ 35.4 Billion in 2025, growing at a CAGR of 10.3% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 36.7% share with a revenue of US$ 13.0 Billion.

The global Biologics Contract Manufacturing Market is experiencing significant growth due to the rising demand for biologic drugs, increasing prevalence of chronic diseases, and expanding pharmaceutical outsourcing activities. Biologics contract manufacturing involves third-party companies providing development and production services for biologic products such as monoclonal antibodies, vaccines, recombinant proteins, cell therapies, and gene therapies. Pharmaceutical and biotechnology companies increasingly rely on contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) to reduce operational costs, improve production efficiency, and accelerate product commercialization.

The market is benefiting from rapid advancements in bioprocessing technologies, single-use systems, and large-scale biologics production capabilities. Growing investments in research and development activities, along with rising approvals of biologic therapies, are further supporting market expansion. Additionally, the increasing focus on personalized medicine and biosimilars is creating new opportunities for contract manufacturers worldwide.

North America currently dominates the market due to strong biopharmaceutical infrastructure and high R&D spending, while Asia-Pacific is emerging as a fast-growing region driven by lower manufacturing costs, expanding biotechnology industries, and supportive government initiatives aimed at strengthening pharmaceutical production capacities.

Click here for more information: https://market.us/report/biologics-contract-manufacturing-market/

*Key Takeaways
*
2025 Market Revenue: US$ 35.4 Billion

Expected Market Value by 2035: US$ 94.4 Billion

CAGR (2026-2035): 10.3%

Leading Product Type: Monoclonal Antibodies

Monoclonal Antibodies Market Share: 44.9%

Other Product Types: Vaccines, Gene Therapy, Cell Therapy, Others

Leading Indication Segment: Oncology

Oncology Market Share: 46.3%

Other Indications: Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Others

Leading Region: North America

North America Market Share: 36.7%
**

Key Market Segments
By Product Type
**

Monoclonal Antibodies
Vaccines
Gene Therapy
Cell Therapy
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Other
Market Key Players
Top Key Players
Thermo Fisher Scientific
Samsung Biologics
Lonza Group
Catalent
Samsung Bioepis
Fujifilm Diosynth Biotechnologies
Wuxi Biologics
BioVectra
Boehringer Ingelheim BioXcellence
AGC Biologics

Get a Sample Copy of the Report to Know More: https://market.us/report/biologics-contract-manufacturing-market/free-sample/

**Market Dynamics

Driver

**
The growing demand for biologic therapies is a major driver of the biologics contract manufacturing market. Biologics, including monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies, are increasingly used to treat chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions. According to the U.S. Food and Drug Administration (FDA), biologics account for a rapidly increasing share of newly approved medicines, reflecting the strong shift toward advanced therapeutic solutions. The World Health Organization (WHO) estimates that cancer caused nearly 10 million deaths globally in 2022, increasing the demand for innovative oncology biologics and targeted therapies.

Pharmaceutical and biotechnology companies are increasingly outsourcing manufacturing activities to contract development and manufacturing organizations (CDMOs) to reduce production costs, access specialized expertise, and accelerate commercialization timelines. Biologic manufacturing requires advanced bioprocessing facilities, strict regulatory compliance, and highly skilled professionals, making outsourcing a cost-effective solution. Additionally, rising investments in biotechnology research are supporting market expansion. According to the U.S. National Institutes of Health (NIH), billions of dollars are invested annually in biomedical research, contributing to continuous biologics development and increasing demand for contract manufacturing services globally.

Trend

The adoption of advanced bioprocessing technologies and single-use manufacturing systems is a key trend shaping the biologics contract manufacturing market. Biopharmaceutical companies are increasingly utilizing disposable bioreactors, automated production systems, and continuous manufacturing technologies to improve operational efficiency and reduce contamination risks. Single-use systems help manufacturers minimize cleaning requirements, lower water consumption, and shorten production turnaround times. According to the U.S. Food and Drug Administration (FDA), continuous manufacturing technologies can significantly improve product consistency and manufacturing flexibility in pharmaceutical production.

Another major trend is the growing focus on cell and gene therapies. The U.S. FDA has projected that it may approve dozens of cell and gene therapy products annually as the pipeline for advanced therapies continues to expand. This growth is increasing the demand for specialized contract manufacturing services capable of handling complex biologic production processes. In addition, digital technologies such as artificial intelligence, process analytics, and automation are being integrated into biologics manufacturing to optimize quality control and production efficiency. The increasing use of personalized medicine and biosimilars is also encouraging manufacturers to expand biologics production capacity globally.

Restraint

High manufacturing complexity and strict regulatory requirements remain major restraints for the biologics contract manufacturing market. Biologic drugs are produced using living cells and highly sensitive biological processes, making manufacturing more complicated than traditional pharmaceutical production. Maintaining product consistency, sterility, and quality requires advanced infrastructure, specialized equipment, and skilled personnel. According to the U.S. Food and Drug Administration (FDA), biologics manufacturing facilities must comply with rigorous Current Good Manufacturing Practice (CGMP) regulations to ensure product safety and effectiveness.

Establishing biologics production facilities also requires substantial capital investment. Large-scale bioreactors, cleanroom environments, cold chain systems, and quality testing laboratories significantly increase operational costs. Smaller biotechnology companies may face financial challenges in meeting these requirements. In addition, regulatory approval processes for biologics are lengthy and complex due to strict clinical and manufacturing standards. Manufacturing errors or contamination incidents can lead to costly product recalls and production delays.

Supply chain challenges also affect the market, particularly for temperature-sensitive biologic materials requiring specialized transportation and storage conditions. These operational complexities and high costs may limit market growth, especially for smaller firms and emerging market manufacturers with limited infrastructure capabilities.

Opportunity

The rapid expansion of biosimilars, personalized medicine, and emerging biotechnology industries presents strong opportunities for the biologics contract manufacturing market. Governments and healthcare organizations worldwide are supporting biologic drug development to improve treatment access for chronic and life-threatening diseases. According to the U.S. Food and Drug Administration (FDA), biosimilar approvals have increased steadily in recent years, helping reduce treatment costs and expand patient access to biologic therapies. This growing biosimilar pipeline is creating substantial demand for specialized manufacturing services.

Emerging economies such as India, China, and South Korea are investing heavily in biotechnology infrastructure and pharmaceutical manufacturing capabilities. Supportive government initiatives, lower operational costs, and expanding research ecosystems are attracting global pharmaceutical outsourcing activities to these regions. Additionally, the increasing prevalence of chronic diseases is expected to drive long-term biologics demand. The World Health Organization (WHO) estimates that noncommunicable diseases account for approximately 74% of global deaths annually.

Advancements in cell and gene therapy manufacturing also provide future growth opportunities. Contract manufacturers that invest in advanced bioprocessing technologies, automation, and flexible production facilities are expected to benefit from increasing demand for innovative biologic therapies and personalized treatment solutions worldwide.

Conclusion

The biologics contract manufacturing market is expected to experience substantial growth in the coming years due to the increasing demand for biologic therapies, rising prevalence of chronic diseases, and expanding pharmaceutical outsourcing activities. Biopharmaceutical companies are increasingly partnering with contract development and manufacturing organizations (CDMOs) to reduce operational costs, improve production efficiency, and accelerate product commercialization. Technological advancements in bioprocessing, automation, single-use systems, and continuous manufacturing are further enhancing production capabilities and supporting market expansion.

The growing adoption of monoclonal antibodies, biosimilars, cell therapies, and gene therapies is creating long-term opportunities for contract manufacturers worldwide. North America currently leads the market due to its advanced biotechnology infrastructure and strong research investments, while Asia-Pacific is emerging as a major manufacturing hub because of lower operational costs and supportive government initiatives.

However, high production complexity, strict regulatory requirements, and significant capital investment needs remain key challenges for market participants. Despite these restraints, increasing healthcare investments, expanding biologics pipelines, and advancements in personalized medicine are expected to drive sustained market growth, making biologics contract manufacturing an essential component of the global biopharmaceutical industry.

Bioimpedance Devices Industry Outlook Remains Positive Through 2035

phenix samsung — Wed, 27 May 2026 11:53:43 +0000

Report Overview

The Global Bioimpedance Devices Market size is expected to be worth around US$ 1330.7 Million by 2035 from US$ 695.7 Million in 2025, growing at a CAGR of 6.7% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 36.9% share with a revenue of US$ 256.7 Million.

The global Bioimpedance Devices Market is witnessing steady growth due to increasing awareness regarding body composition analysis, chronic disease management, and preventive healthcare practices. Bioimpedance devices are non-invasive medical tools used to measure body fat, muscle mass, hydration levels, and overall body composition by analyzing the resistance of body tissues to electrical currents. These devices are widely utilized in hospitals, fitness centers, sports medicine, home healthcare, and research institutions.

Rising cases of obesity, diabetes, cardiovascular diseases, and kidney disorders are significantly driving demand for bioimpedance technologies worldwide. Healthcare providers are increasingly adopting these devices for nutritional assessment, fluid monitoring, and patient health management. Technological advancements such as wireless connectivity, portable analyzers, cloud-based monitoring, and AI-enabled analytics are further improving device efficiency and accessibility.

North America currently leads the market due to strong healthcare infrastructure and growing adoption of digital health technologies, while Asia-Pacific is emerging as a high-growth region because of rising healthcare awareness and expanding fitness industries. Increasing geriatric populations and the growing focus on personalized healthcare solutions are expected to create additional opportunities for market expansion during the coming years.

Click here for more information: https://market.us/report/bioimpedance-devices-market/

Key Takeaways

In 2025, the global Bioimpedance Devices Market accounted for US$ 695.7 Million in revenue and is projected to reach US$ 1,330.7 Million by 2035, expanding at a CAGR of 6.7% during the forecast period.
Based on product type, the market is categorized into multi-frequency, dual-frequency, and single-frequency devices. Among these, the multi-frequency segment dominated the market with a 48.9% share.
By modality, the market is segmented into wired and wireless systems, with wired devices capturing a leading market share of 57.2%.
In terms of application, the market is divided into whole-body and segmental analysis. The whole-body segment held the largest revenue contribution, accounting for 62.6% of the market.
North America emerged as the leading regional market, securing a dominant market share of 36.9% in 2025.

Key Market Segments

By Product Type
**

Multi-frequency
Dual-frequency
Single-frequency
By Modality
Wired
Wireless
By Application
Whole-body
Segmental
Market Key Players
InBody
Tanita
seca
Bodystat
Maltron International
Omron Healthcare
RJ-L Systems
Fresenius Medical Care
Withings
Hologic

Get a Sample Copy of the Report to Know More: https://market.us/report/bioimpedance-devices-market/free-sample/

Market Dynamics

Driver

The growing global burden of obesity, diabetes, and cardiovascular diseases is a major driver for the bioimpedance devices market. Bioimpedance devices are increasingly used to assess body composition, hydration status, fat mass, and muscle distribution because they offer non-invasive, rapid, and cost-effective analysis. According to the World Health Organization (WHO), in 2022 around 2.5 billion adults worldwide were overweight, including 890 million living with obesity. Additionally, 43% of adults aged 18 years and older were overweight, while 16% were obese. (World Health Organization) Rising obesity levels are increasing demand for body composition monitoring in hospitals, fitness centers, sports medicine, and home healthcare settings. Bioimpedance analysis is also becoming important in chronic disease management, especially for diabetes and kidney disease patients where fluid balance monitoring is essential. Governments and healthcare organizations are promoting preventive healthcare and early disease screening programs, further supporting adoption. In India and other Asian countries, clinicians increasingly recognize that traditional BMI measurements may underestimate metabolic risks, encouraging broader use of advanced body composition technologies such as bioimpedance analyzers for more accurate health assessments.

Trend

A major trend in the bioimpedance devices market is the integration of digital health technologies, wearable systems, and AI-enabled monitoring platforms. Modern bioimpedance devices now provide wireless connectivity, cloud-based analytics, smartphone synchronization, and real-time health tracking. This trend aligns with the broader shift toward personalized healthcare and remote patient monitoring. Healthcare providers increasingly use bioimpedance systems to track nutritional status, muscle wasting, and fluid retention among elderly patients and individuals with chronic illnesses. Research communities are also moving beyond conventional BMI assessments toward body composition-based evaluation. Studies and public health discussions have highlighted that BMI alone may misclassify obesity risks in many individuals, especially among Asian populations and elderly adults. (Reddit) The increasing popularity of fitness applications and smart health devices is accelerating consumer adoption of portable bioimpedance analyzers. In addition, sports medicine and wellness industries are using multi-frequency bioimpedance technologies for athlete performance optimization. The expansion of telemedicine services after the COVID-19 pandemic has further increased interest in home-based monitoring tools, creating strong demand for connected bioimpedance devices capable of continuous and convenient body composition analysis.

Restraint

One of the major restraints in the bioimpedance devices market is the limited accuracy and variability of measurements compared with advanced imaging technologies such as Dual-Energy X-ray Absorptiometry (DEXA), MRI, and CT scans. Bioimpedance readings can be affected by hydration levels, age, food intake, physical activity, and device calibration, which may reduce diagnostic consistency. Healthcare professionals often view bioimpedance analysis as a supportive screening tool rather than a definitive diagnostic method. Concerns regarding misclassification of obesity and body composition remain significant. Recent studies have shown that BMI and certain body measurement techniques may incorrectly classify large patient populations, creating challenges in standardizing obesity diagnosis. (The Washington Post) Additionally, lack of universal clinical guidelines for bioimpedance interpretation across different ethnic populations limits broader medical adoption. In low- and middle-income countries, high costs of advanced multi-frequency bioimpedance systems and limited reimbursement policies also restrict market penetration. Regulatory approval requirements for medical-grade devices can increase development costs for manufacturers. Furthermore, some physicians continue to rely on traditional anthropometric methods because they are inexpensive and widely available, slowing the transition toward advanced body composition technologies in routine healthcare practice.

Opportunity

The increasing emphasis on preventive healthcare, geriatric care, and chronic disease management presents substantial opportunities for the bioimpedance devices market. Global healthcare systems are facing rising cases of obesity, diabetes, heart disease, and kidney disorders, all of which require regular monitoring of body composition and fluid balance. WHO estimates indicate that obesity rates have more than doubled globally since 1990, while childhood obesity continues to rise rapidly. (World Health Organization) This growing health burden is encouraging governments and healthcare providers to adopt technologies that support early diagnosis and long-term disease management. Bioimpedance devices have strong growth potential in dialysis centers, oncology care, elderly nutrition monitoring, and rehabilitation programs. Aging populations are another key opportunity area, as older adults are highly vulnerable to sarcopenia, dehydration, and malnutrition. Portable and home-use bioimpedance analyzers are becoming increasingly attractive due to their convenience and affordability. Emerging markets such as India, China, and Southeast Asia also offer major expansion potential because of rising healthcare awareness and growing fitness culture. Integration with telehealth platforms and AI-driven predictive analytics may further enhance clinical usefulness and expand applications in personalized medicine and remote patient monitoring.

CONCLUSION

The Bioimpedance Devices Market is expected to experience steady growth over the coming years, driven by the increasing prevalence of obesity, diabetes, cardiovascular diseases, and other chronic health conditions that require continuous body composition and fluid monitoring. The growing adoption of non-invasive diagnostic technologies, combined with rising awareness regarding preventive healthcare and fitness management, is further supporting market expansion. Technological advancements such as wireless connectivity, portable monitoring systems, and AI-integrated health tracking solutions are also enhancing the efficiency and accessibility of bioimpedance devices across clinical and homecare settings.

The dominance of multi-frequency devices highlights the growing demand for accurate and comprehensive body composition analysis, while the strong presence of wired systems reflects their continued reliability in healthcare facilities. The whole-body application segment continues to lead due to its broad clinical and fitness-related usage. Regionally, North America maintains a leading position owing to advanced healthcare infrastructure and higher adoption of digital health technologies. Meanwhile, emerging economies are expected to create significant future opportunities due to expanding healthcare investments, increasing health awareness, and the rapid growth of fitness and wellness industries.

Aspiration & Biopsy Needles Market Expected to Achieve US$ 1.5 Billion Valuation by 2035

phenix samsung — Wed, 27 May 2026 06:32:14 +0000

Report Overview

The Global Aspiration & Biopsy Needles Market size is expected to be worth around US$ 1.5 Billion by 2035 from US$ 0.8 Billion in 2025, growing at a CAGR of 6.3% during the forecast period 2026-2035. In 2025, North America led the market, achieving over 38.7% share with a revenue of US$ 0.3 Billion.

The growing prevalence of cancer and other chronic diseases is fueling demand for aspiration and biopsy needles, as healthcare providers increasingly prefer minimally invasive diagnostic procedures that enable precise tissue sampling, lower patient discomfort, and quicker recovery. Interventional radiologists are widely utilizing ultrasound-guided fine-needle aspiration procedures for thyroid nodules to accurately distinguish between benign and malignant conditions, supporting faster and more effective treatment decisions.

Click here for more information: https://market.us/report/aspiration-biopsy-needles-market/

Key Takeaways
In 2025, the Aspiration & Biopsy Needles Market generated revenue of US$ 0.8 Billion and is projected to reach US$ 1.5 Billion by 2035, expanding at a CAGR of 6.3% during the forecast period.
Based on product type, the market is categorized into biopsy needles and aspiration needles. Among these, biopsy needles dominated the segment with a market share of 58.4% in 2025.
By procedure, the market is segmented into image-guided and non-image-guided techniques. The image-guided segment accounted for a leading market share of 63.7%.
In terms of application, the market is divided into tumour/cancer, wounds, and others. The tumour/cancer segment emerged as the largest contributor, capturing 54.9% of the total market revenue.
Considering end users, the market includes hospitals & surgical centers, diagnostic clinics & pathology laboratories, ambulatory care centers, and research & academic institutes. Hospitals & surgical centers held the dominant position with a revenue share of 57.6%.
North America remained the leading regional market in 2025, accounting for a 38.7% market share.
Key Market Segments
By Product Type
Biopsy Needles
Aspiration Needles
By Procedure
Image-guided
Non-image-guided
By Application
Tumour/Cancer
Wounds
Others
By End-user
Hospitals & Surgical Centers
Diagnostic Clinics & Pathology Laboratories
Ambulatory Care Centers
Research & Academic Institutes
Market Key Players
Becton Dickinson
Boston Scientific
Cook Medical
Medtronic
Olympus Corporation
Argon Medical Devices
Merit Medical Systems
Cardinal Health
Hologic
Stryker

Get a Sample Copy of the Report to Know More: https://market.us/report/aspiration-biopsy-needles-market/free-sample/

Market Dynamics
Driver

The rising global burden of cancer and chronic diseases is a major factor driving the Aspiration & Biopsy Needles Market. Biopsy procedures are essential for confirming cancer diagnosis, determining disease stage, and guiding treatment decisions. According to the World Health Organization (WHO), cancer caused nearly 9.7 million deaths worldwide in 2022, while approximately 20 million new cancer cases were reported globally. Increasing incidence of breast, lung, colorectal, thyroid, and prostate cancers has significantly raised demand for minimally invasive biopsy procedures.

Needle biopsy procedures are increasingly preferred because they reduce surgical trauma, shorten hospital stays, and lower healthcare costs compared to open surgical biopsies. The U.S. National Cancer Institute states that biopsy remains the primary method for confirming cancer diagnosis in most patients. Fine-needle aspiration and core biopsy procedures are widely used in breast, liver, kidney, and thyroid examinations.

In addition, aging populations contribute to market expansion, as cancer risk rises significantly with age. Growing awareness regarding early diagnosis and increasing adoption of image-guided procedures across hospitals and diagnostic centers further support long-term market growth.

Trend

A major trend shaping the Aspiration & Biopsy Needles Market is the growing adoption of image-guided biopsy procedures using ultrasound, CT, MRI, and fluoroscopy technologies. Healthcare providers increasingly prefer image-guided techniques because they improve precision, reduce complications, and enhance diagnostic accuracy. The National Center for Biotechnology Information (NCBI) recognizes image-guided biopsy as an important advancement in minimally invasive diagnostics.

Hospitals are rapidly integrating advanced imaging systems with biopsy devices to target deep or difficult-to-access lesions. Recent clinical data published through the German Society for Interventional Radiology registry analyzed 5,235 image-guided renal biopsy procedures conducted between 2018 and 2024 across 176 medical centers, demonstrating growing procedural adoption and improved procedural safety. CT guidance represented over 78% of procedures in the study.

Another emerging trend involves robotic-assisted and AI-supported biopsy technologies that improve needle placement accuracy. MRI-guided breast biopsy systems are gaining attention for detecting small or hidden lesions with high precision. Additionally, outpatient biopsy procedures are increasing due to faster recovery times and lower healthcare expenditures. These technological advancements are transforming diagnostic workflows and improving patient outcomes globally.

Restraint

Despite strong growth potential, the Aspiration & Biopsy Needles Market faces restraints associated with procedural complications, high equipment costs, and limited access to advanced diagnostic infrastructure in developing regions. Although minimally invasive, biopsy procedures can still cause bleeding, infection, pain, or tissue damage, especially in high-risk patients or complex organ biopsies. Concerns regarding false-negative results or inadequate tissue sampling may also affect diagnostic reliability.

Advanced image-guided biopsy systems require significant investment in CT, MRI, or ultrasound equipment, which can create financial pressure for smaller hospitals and diagnostic centers. According to WHO surveys conducted across 115 countries, many healthcare systems still lack sufficient funding for cancer diagnostic and treatment services under universal healthcare programs.

In low- and middle-income countries, shortages of trained radiologists, pathologists, and interventional specialists further limit adoption of advanced biopsy technologies. Delayed diagnosis remains a major challenge in underserved regions due to inadequate screening infrastructure and limited healthcare accessibility. Additionally, strict regulatory approval processes for new biopsy devices and growing concerns regarding needlestick injuries among healthcare workers may slow product commercialization and market penetration in certain countries.

Opportunity

The Aspiration & Biopsy Needles Market presents strong opportunities through expanding cancer screening programs, technological innovation, and increasing healthcare investments in emerging economies. Governments and healthcare organizations are emphasizing early cancer detection to reduce mortality and treatment costs. The WHO estimates that nearly one-third of cancer deaths can be prevented through early diagnosis and timely treatment interventions.

Rising awareness regarding preventive healthcare is increasing the number of diagnostic procedures performed annually. Colorectal cancer alone accounts for nearly 10% of global cancer cases, creating substantial demand for tissue sampling and biopsy-based diagnosis.

Emerging economies in Asia-Pacific, Latin America, and the Middle East are investing heavily in hospital infrastructure, diagnostic imaging, and oncology care. These investments create opportunities for manufacturers to introduce cost-effective disposable biopsy needles and portable image-guided systems. Technological developments such as robotic-assisted biopsies, AI-enabled imaging analysis, and vacuum-assisted biopsy devices are also expected to improve procedural efficiency and diagnostic precision.

Furthermore, increasing outpatient and ambulatory surgical procedures provide new revenue opportunities for healthcare providers and device manufacturers. Expansion of telemedicine-supported pathology and remote diagnostics may further enhance access to biopsy services in rural and underserved regions.

Conclusion

The Aspiration & Biopsy Needles Market is poised for steady growth over the coming years, driven by the rising prevalence of cancer and chronic diseases, increasing demand for minimally invasive diagnostic procedures, and advancements in image-guided biopsy technologies. Growing awareness regarding early disease detection and expanding healthcare infrastructure are further supporting market expansion across developed and emerging regions. North America continues to dominate the market due to strong healthcare systems, high adoption of advanced diagnostic technologies, and increasing cancer screening initiatives. Additionally, innovations in robotic-assisted and AI-enabled biopsy procedures are expected to enhance diagnostic accuracy and patient outcomes. As hospitals and diagnostic centers continue to prioritize precision diagnostics and outpatient care, the demand for aspiration and biopsy needles is anticipated to remain strong, creating significant growth opportunities for manufacturers and healthcare providers worldwide through 2035.

Global Angiography Devices Market to Reach US$ 21.7 Billion by 2035 at 6.2% CAGR

phenix samsung — Fri, 22 May 2026 10:18:13 +0000

: //market.us/report/global-angiography-devices-market/q